By using various ferroptosis inducers and inhibitors, they have shown that NRF2-deficient AML cells are particularly sensitive to ferroptosis inducers and that NRF2-induced GPX4 supports AML cell survival against drug treatment. Here, GPX4 is linked to acute myeloid leukemia.